While this previous study only reported that the therapeutic outcome of T + A might be affected by Treg/Tef ratio in the gene expression level, our study further verified the prognostic value of Treg/Tef lymphocytes infiltration ratio in T + A-treated HCC patients and even all HCC patients, which is a supplement and extension of previous research. The gene discussed is TEF; the disease is hepatocellular carcinoma.